The Gates Biomanufacturing Facility signed a continued strategic agreement with Nkarta to manufacture clinical supply of therapeutic Natural Killer cells. As part of this collaboration, GBF will continue to manufacture NKX101, an immunotherapy currently in a Phase I clinical trial for patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
[Gates Biomanufacturing Facility]
7992332
{7992332:nan}
apa
50
1
167660
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
